With 35 years on the market, CCDRD is a high-level clinical CRO for Phase I-IV trials. We have conducted more than 100 pharmacokinetic and pharmacodynamic studies on a wide range of inhaled drugs, including tiotropium, budesonide/formoterol, salmeterol, salbutamol, fluticasone, indacaterol, and glycopyrronium in both healthy volunteers and patients.

Our highly skilled teams specialize in developing special protocols for standardized inhalation procedures, as well as validated bioanalytical methods with exceptionally low limits of quantification. These refined methodologies, combined with volunteer training, double-dummy and charcoal blockade procedures, have significantly reduced intra-subject variances—enhancing the reliability and precision of study outcomes.

CCDRD has established streamlined workflows and rigorous study protocols for inhaled products, ensuring a high degree of standardization and optimized clinical trial execution. We provide high-level clinical services to pharmaceutical and biotech companies seeking to conduct trials with inhalation therapies.

Our Expertise Includes:

• Standardized inhalation procedures for Dry Powder Inhalers (DPI) and Metered-Dose Inhalers (MDI)
• Specialized inhaler training to ensure consistent drug administration
• Phase I units equipped for spirometry and PK sampling
• Hands-on experience with various inhalation devices, including Diskus®, HandiHaler®, Turbohaler®, Spiromax®, Forspiro®, and more
• Structured workflows and study protocols tailored for inhalation products
• Small dosing groups for optimized study design
• Advanced clinical techniques, including double-dummy and charcoal-blockade procedures
• Highly sensitive, validated analytical methods for accurate assessment of inhaled active pharmaceutical ingredients (APIs)

At CCDRD, we are committed to delivering high-quality, precise, and reliable clinical research solutions for inhalation products.